Markets open

Incyte Corp.

INCY · NASDAQ-GS

Analyst Consensus

Hold

18 analysts

$113

Current

—

Low

$130

Average

—

High

Average target implies +14.62% versus the current price.

Analyst Ratings Synthesis

The supplied consensus field is unknown, so no authoritative consensus rating or analyst count can be stated. Third-party snippets nevertheless show a fragmented picture: Public reports a Buy consensus from 20 analysts with a $107.60 target; TipRanks cites 20 analysts, a $113.65 average, and a $94-$140 range; ChartMill cites 32 analysts and a $101.70 average; and Simply Wall St references targets roughly between $117 and $128, including a reset from $114.55 to $124.96. The most bullish cited source is Simply Wall St, while ChartMill is least bullish on average. No named analyst or firm-level actions, and no revisions specifically during this week, are supplied. The substantive disagreement is the value assigned to growth, Phase 3 catalysts, and the post-Jakafi outlook.

Rating Actions

No individual rating actions have been captured for INCY yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BMO CAPITAL MKT

CITIGROUP

CITIZENS JMP

GOLDMAN SACHS

GUGGENHEIM SEC.

JP MORGAN SECUR

LEERINK PARTNRS

MIZUHO SECURITI

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RBC CAPITAL

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

WILLIAM BLAIR

Symbol: INCY
Type: Stock
Sector: Health Care
Industry: Biotechnology: Commercial Physical & Biological Resarch
Country: North America
Exchange: NASDAQ-GS

Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

Key Issues

Bullish view

FY2025 revenue increased to $5.1 billion from $4.2 billion, and DirectorsTalk describes a 37.7% revenue-growth surge, supporting the case for continued momentum.

Bearish view

The evidence does not identify which products or customers produced the growth, leaving uncertainty about its durability and concentration. Without segment data or forward guidance, the reported increase may not establish a continuing trend.

Analyst Consensus

See all

Hold

18 analysts

$113

Current

—

Low

$130

Average

—

High

Average target implies +14.62% versus the current price.

Earnings History

BeatMissNo estimate

Incyte Corp.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers